What is 7-hydroxymitragynine?

The short version

7-Hydroxymitragynine (7-OH) is an indole alkaloid found in the leaves of the kratom tree. It binds to the same brain receptors as morphine — with roughly 13 times the binding affinity (Obeng et al., 2021) — but it activates those receptors differently. It's a partial agonist, not a full one, and it preferentially triggers G-protein signaling while largely ignoring the beta-arrestin pathway. Those distinctions matter pharmacologically, even if the marketing around them often overpromises.

The plant: Mitragyna speciosa

Kratom (Mitragyna speciosa) is a tropical evergreen in the coffee family (Rubiaceae), native to Thailand, Malaysia, Indonesia, Myanmar, and Papua New Guinea. Its leaves have been chewed, brewed as tea, and smoked in Southeast Asia for at least two centuries — primarily by laborers and farmers as a stimulant to combat fatigue, and traditionally as folk medicine for pain, diarrhea, cough, and hypertension.

Thailand banned kratom cultivation under the Kratom Act of 1943 (largely to protect opium tax revenue), then legalized medicinal use again in 2018. In Malaysia, it remains controlled. In the West, kratom arrived primarily as a dietary supplement and has grown into a multi-billion dollar industry — though the FDA has never approved it for any medical use.

The plant contains over 40 identified alkaloids. Most of the pharmacological action traces back to two: mitragynine (the most abundant) and 7-hydroxymitragynine (the most potent).

Where 7-OH fits in the alkaloid profile

Kratom's alkaloid chemistry varies by geography, genetics, season, and leaf maturity — but some patterns are consistent (Berthold et al., 2022):

• Mitragyninemakes up roughly 66% of total alkaloid content in Thai varieties (lower in Malaysian varieties, around 12%). It's the most abundant active compound.
• 7-Hydroxymitragynine accounts for about 1–2% of total alkaloid content. In terms of dry leaf weight, concentrations range from 0.003% to 0.04% depending on origin and growing conditions. Some studies have detected it only in specific seasons.
• Paynantheine (second most abundant) and speciogynine(third) are smooth muscle relaxers that contribute to kratom's overall effect profile but have far less opioid receptor activity.

Total alkaloid concentration in dried leaves typically ranges from 0.5% to 1.5%. So in a gram of dried kratom leaf, you might find 3–6 mg of mitragynine and 0.03–0.15 mg of 7-hydroxymitragynine. For context, a single commercial 7-OH tablet can contain 10–80 mg of concentrated 7-hydroxymitragynine — orders of magnitude more than what exists in whole leaf.

How 7-OH works at the receptor level

7-Hydroxymitragynine is a partial agonist at mu-opioid receptors (MOR) — the same receptor class activated by morphine, codeine, and fentanyl. It also shows antagonist activity at delta and kappa opioid receptors.

The binding numbers from published research:

• Mu-opioid receptor (MOR): K_i = 37 ± 4 nM
• Delta-opioid receptor (DOR): K_i = 91 ± 8 nM
• Kappa-opioid receptor (KOR): K_i = 132 ± 7 nM

In functional assays, 7-OH is approximately 10-fold more potent than morphine and 40-fold more potent than mitragynine in antinociception (pain response) tests. In mouse tail-flick and hot-plate tests, subcutaneous 7-OH produced antinociceptive effects 5.7x and 4.4x more potent than morphine, respectively (Matsumoto et al., 2004).

The word “partial” matters here. Unlike morphine (a full agonist that can maximally activate the receptor), 7-OH produces a submaximal response — its E_maxat the human MOR is about 47%, compared to mitragynine's 34%. This ceiling on receptor activation is pharmacologically significant, though how much it translates to real-world safety is actively debated.

G-protein bias and the beta-arrestin question

This is the most scientifically interesting — and most overhyped — aspect of 7-OH pharmacology.

When an opioid binds to a mu-opioid receptor, it can activate two downstream signaling cascades: G-protein signaling (associated with pain relief) and beta-arrestin-2 recruitment (historically linked to side effects like respiratory depression and constipation). A compound that preferentially activates G-protein signaling over beta-arrestin is called a “biased agonist.”

Both mitragynine and 7-hydroxymitragynine display G-protein–biased agonism at MOR, with no measurable recruitment of beta-arrestin-2 in standard assays (Gutridge et al., 2020). This generated excitement in the research community, because it suggested kratom alkaloids might provide analgesia with fewer classical opioid side effects.

The caveat:The hypothesis that beta-arrestin-2 avoidance automatically equals safer opioids has come under serious scrutiny. Researchers have noted that “current evidence does not support a direct or uniform causal relationship between reduced beta-arrestin-2 recruitment and improved safety.” The oliceridine (TRV130) story — a G-protein-biased opioid that still caused respiratory depression in clinical trials — is a cautionary example. G-protein bias is pharmacologically interesting but should not be confused with a safety guarantee.

Metabolism: the mitragynine-to-7-OH conversion

A landmark 2019 study in ACS Central Science demonstrated that 7-hydroxymitragynine is an active metabolite of mitragynine — meaning your body converts mitragynine into 7-OH after you consume kratom. This conversion is catalyzed by hepatic cytochrome P450 3A4 (CYP3A4) enzymes, with contributions from CYP2C19 and CYP2D6 (Kamble et al., 2020).

The study found that brain concentrations of metabolically-produced 7-OH are “sufficient to explain most or all of the opioid-receptor-mediated analgesic activity of mitragynine.” In other words, when you take regular kratom, much of the opioid-like effect you feel may actually come from 7-OH that your liver created from the mitragynine.

This has several practical implications:

• CYP3A4 inhibitors (grapefruit juice, ketoconazole, certain medications) can alter the rate of conversion, potentially changing both the intensity and duration of effects
• Individual variation in CYP enzyme expression means the same dose of kratom or 7-OH can produce very different blood levels of active compound between people
• Drug interactions with other CYP3A4 substrates are pharmacologically plausible and clinically relevant

Natural leaf vs. commercial 7-OH products

This is where the conversation shifts from academic pharmacology to public health policy. The gap between natural kratom and commercial 7-OH products is enormous:

The production pipeline for commercial 7-OH: manufacturers purchase purified mitragynine in bulk (often kilogram quantities from international labs), then chemically oxidize it to attach a hydroxyl group at the 7-position. The result is semi-synthetic 7-hydroxymitragynine at near-pharmaceutical purity. A 2025 market survey identified 304 commercial 7-OH products — 82% sold as 7-OH only, formulated as chewable tablets, sublingual tablets, shots, or gummies.

This distinction — trace-level natural occurrence vs. industrially concentrated product — is central to the FDA's regulatory position and to several state-level bans. States like Tennessee explicitly differentiate: natural kratom is legal for adults, but concentrated or synthetic 7-OH is restricted.

Putting the potency numbers in context

You'll see claims that 7-OH is “13x stronger than morphine” or “46x stronger than mitragynine.” These numbers come from real research, but they need context:

• The 13x morphine figure refers to binding affinity at the mu-opioid receptor in vitro — how tightly the molecule grips the receptor, not how strong the subjective effects are
• In functional antinociception tests (measuring actual pain response in mice), the potency ratio is lower: about 5–10x morphine
• The partial agonist ceilingmeans increasing the dose past a certain point doesn't proportionally increase the effect. At max receptor occupancy, 7-OH produces about 47% of the response that a full agonist would. Morphine doesn't have that ceiling.
• Potency ≠ danger in a simple linear way. Fentanyl is 100x more potent than morphine and extraordinarily dangerous. 7-OH is 10x more potent than morphine with a partial-agonist ceiling — a fundamentally different risk profile.

None of this means 7-OH is safe. It means the “X-times-stronger-than-morphine” framing, used both by marketers and by regulators, oversimplifies the pharmacology. For detailed comparisons, see 7-OH vs morphine and 7-OH vs mitragynine.

What 7-OH actually feels like

The pharmacology papers describe receptor binding affinities and signaling pathways. Here's what people actually report when they take commercial 7-OH products:

The positive experiences

At low to moderate doses, users commonly describe a warm, enveloping sense of physical comfort — the body relaxes, background pain diminishes or disappears, and there's a mood lift that ranges from subtle contentment to noticeable euphoria. People describe it as feeling “wrapped in a warm blanket” — an analgesic warmth that's distinct from the stimulating energy that low-dose traditional kratom provides.

For people dealing with chronic pain, the appeal is obvious: reliable, fast-acting relief in a convenient tablet. Users managing conditions like back pain, arthritis, fibromyalgia, and neuropathy report that 7-OH provides meaningful analgesia — in some cases after cycling through prescription options that either stopped working or came with intolerable side effects. Social anxiety reduction and improved sleep are also frequently mentioned.

The onset is relatively quick — 15 to 30 minutes for sublingual or chewable formats, 30 to 45 minutes for tablets. Duration is typically 3 to 5 hours, shorter than many traditional kratom preparations.

The neutral reality

The effects are dose-dependent and vary significantly between individuals. What produces mild relaxation in one person can cause heavy sedation in another at the same dose — partly due to CYP enzyme variation, body weight, tolerance, and whether you've eaten. Nausea is common, especially at higher doses or for new users, and it can be enough to ruin the experience entirely. Some people get the “wobbles” — dizziness and eye instability — that experienced kratom users will recognize. Constipation is near-universal with regular use, consistent with any opioid-receptor-active compound.

The effects are also short-lived compared to traditional kratom, which means redosing temptation is high. This is one of the mechanisms driving the escalation pattern described below.

The dark side: dependence and escalation

This is the part that doesn't make it into the marketing — and it's the reason regulators are paying attention.

The most consistent pattern in user reports is rapid tolerance and dose escalation. People who start with one tablet find themselves at two within a week, then four, then more. A 2024 analysis of kratom subredditsfound that discussions about 7-OH products frequently included phrases like “escalated quickly,” “didn't expect to get dependent,” and “harder to quit than regular kratom.”

One frequently cited user trajectory: starting with half a tablet of 7-OH out of curiosity, escalating to 8–10 tablets per day within weeks, and then discovering that stopping produces genuine opioid-type withdrawal — muscle pain, insomnia, restlessness, sweating, anxiety, and gastrointestinal distress.

A high-affinity partial agonist at mu-opioid receptors will produce tolerance and dependence with regular use. This is not a possibility — it's a near-certainty.

The withdrawal timeline is also steeper than traditional kratom. Users report acute symptoms hitting within 6–12 hours of the last dose (faster than whole-leaf kratom), peaking at days 1–3, and lingering with post-acute symptoms — brain fog, mood instability, cravings — for weeks or sometimes months. The concentrated, single-alkaloid nature of 7-OH products (as opposed to the buffered, multi-alkaloid profile of whole leaf) appears to produce a sharper dependence curve.

Financial strain is another underreported consequence. At $1–3 per tablet and doses escalating to 8+ tablets per day, a 7-OH habit can quickly cost $200–500+ per month.

7-OH and pain management

An estimated 50 million Americans live with chronic pain. Many have cycled through NSAIDs, gabapentinoids, and prescription opioids — facing either inadequate relief, intolerable side effects, or the increasingly difficult task of getting opioid prescriptions renewed in a post-crisis regulatory environment. This is the population driving much of the demand for 7-OH products.

Why people turn to 7-OH for pain

The logic is straightforward: 7-hydroxymitragynine is an effective analgesic that's legal (in most states), available without a prescription, and sold at gas stations and smoke shops. For someone whose doctor won't prescribe opioids — or who wants to avoid prescription opioids entirely — it fills a genuine gap. Research from Johns Hopkins found that kratom users reported “a lower rate of harm than prescription opioids for treating pain, anxiety, depression, and addiction.”

Users managing chronic back pain, joint pain, fibromyalgia, surgical recovery, and neuropathic pain report meaningful relief from 7-OH. A cross-sectional study using ecological momentary assessment confirmed that kratom users experienced meaningful acute pain reduction. Some have used it to taper off prescription opioids, replacing a controlled substance with an (as yet) unscheduled one.

The complicated reality

The pain management use case is where 7-OH is simultaneously most promising and most problematic:

• It works for pain — this is supported by the pharmacology (mu-opioid receptor agonism is the gold-standard mechanism for analgesia) and by consistent user reports. Denying that 7-OH provides pain relief is not credible.
• It doesn't treat the underlying condition — like all opioid-receptor-active analgesics, 7-OH manages symptoms. The pain source remains.
• It carries dependence risk — the same mu-opioid receptor activity that provides pain relief also produces tolerance and physical dependence. For chronic pain patients who need daily relief, this is a significant concern.
• It's unregulated — unlike prescription opioids (which have dosing protocols, physician oversight, and quality controls), commercial 7-OH products have variable potency, no standardized dosing, and no medical supervision. A 2025 market survey found significant batch-to-batch inconsistency across brands.
• The FDA has not approved it — 7-OH is not an approved pain treatment. Self-treating chronic pain with an unregulated opioid-receptor agonist carries real risk, especially without medical oversight.

The opioid withdrawal bridge

A subset of 7-OH users are using it specifically to manage opioid withdrawal — essentially substituting one mu-opioid-receptor agonist for another. This is a legitimate harm-reduction strategyin concept (it's essentially what buprenorphinedoes in a clinical setting), but doing it unsupervised with an unregulated product carries obvious risks. If you're considering this route, involving a healthcare provider — even just for monitoring — is strongly advisable. The SAMHSA National Helpline (1-800-662-4357) offers free, confidential referrals 24/7.

What this means for you

If you're exploring 7-OH for pain management, go in with clear eyes:

• It will probably provide pain relief. The pharmacology supports this.
• If you use it daily, you will likely develop tolerance and physical dependence. This is not a possibility — it's a near-certainty with regular mu-opioid receptor agonist use.
• Consider whether the trade-off (effective pain relief vs. dependence risk) makes sense for your specific situation, ideally in conversation with a healthcare provider.
• If you proceed, use the lowest effective dose, take scheduled breaks, buy only from lab-tested brands, and be honest with yourself about whether your use is escalating.

What the safety data actually shows

The safety picture for 7-OH is genuinely mixed. Here's what the evidence says as of early 2026:

Respiratory depression

The beta-arrestin hypothesis suggested 7-OH might cause less respiratory depression than classical opioids. Recent data complicates that: a 2025 study found that both mitragynine and 7-hydroxymitragynine can cause respiratory depression when given intravenously, and that these effects are reversed by naloxone (confirming they're opioid-receptor-mediated). The FDA has linked 7-OH to respiratory depression in adverse event reports.

Dependence and withdrawal

Regular use of 7-OH can produce physical dependence with opioid-type withdrawal symptoms upon cessation — muscle aches, insomnia, irritability, anxiety, gastrointestinal distress. This is consistent with its mu-opioid receptor activity and is not seriously disputed.

Adverse event trends

Kratom-related cases reported to poison control centersrose from under 200 in 2014 to roughly 1,600 in 2024. Approximately 40% of 7-OH reports involved individuals who were misusing the product. Fatalities have been analytically confirmed to involve mitragynine, but “almost all involve use of other substances, so the degree to which kratom use has been a contributory factor to fatalities is unclear” (WHO ECDD pre-review).

The WHO position

In its 2024 pre-review, the WHO Expert Committee on Drug Dependence (ECDD) reviewed kratom, mitragynine, and 7-hydroxymitragynine and concluded: “Kratom can produce serious toxicity in people who use high doses, but the number of cases is probably low as a proportion of the total number of people who use kratom.” The committee recommended surveillance rather than international scheduling.

The regulatory picture

Federal (US)

Kratom is not federally scheduled. However, in July 2025, the FDA formally recommended that the DEA classify 7-hydroxymitragynine as a Schedule I controlled substance — specifically targeting concentrated, semi-synthetic 7-OH products, not natural kratom leaf. The FDA simultaneously issued warning letters to seven companies marketing 7-OH products. The DEA is reviewing the recommendation; scheduling requires a public comment period before finalization.

State level

States have taken divergent approaches. Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin, Connecticut, and Ohio have banned kratom and/or 7-OH outright. Arizona, Oklahoma, Texas, and Utah cap 7-OH at 2% of total alkaloid content under Kratom Consumer Protection Acts. Tennessee allows natural kratom but restricts synthetic 7-OH. Florida's ban is being challenged in court. Full state-by-state breakdown →

International

The WHO ECDD recommended surveillance but not international scheduling. Kratom is banned in several countries including Australia, Denmark, Finland, Israel, Japan, Latvia, Lithuania, Poland, Romania, South Korea, Sweden, and Thailand (now partially re-legalized).

The bottom line

7-Hydroxymitragynine is a pharmacologically potent compound with genuine analgesic properties, an interesting signaling profile, and real risks — especially in the concentrated forms now dominating the consumer market. It's not the “safe, natural opioid alternative” that marketers claim, and it's not the “legal morphine” threat that headline writers suggest. The truth is more complicated and more interesting than either narrative.

If you're considering using 7-OH products, start with the dosage guide, read about side effects, and verify legality in your state. If you're evaluating products, our brand directory covers lab testing practices and transparency.